Back to top

cell-therapy: Archive

Neena Mishra

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

GSKNegative Net Change NVSNegative Net Change PFENegative Net Change MRKPositive Net Change AMGNNegative Net Change GILDPositive Net Change VRTXNegative Net Change IBBNegative Net Change SGENPositive Net Change RXDXPositive Net Change XBINegative Net Change SBIONegative Net Change BTECPositive Net Change IBBQPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

VRTXNegative Net Change CRSPNegative Net Change KALANegative Net Change ALLONegative Net Change